RePORT India is a joint venture between the Indian and U.S. governments. The Indo-U.S. Vaccine Action Program (VAP), a collaboration between the Indian Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), and the U.S. NIH, is co-funding six teams of India- and U.S.-based investigators to implement individual cohort studies of active TB cases and household contacts in India. Investigators are funded to enroll subjects into their own parent protocol. Eligible subjects from each parent protocol will be asked to co-enroll into the RePORT India Common Protocol. All subjects will be enrolled from the sites in India, and are expected to enroll active TB cases and household contacts of active TB cases in their parent protocols. The sites are all experienced in TB clinical research, represent a mix of urban and rural, geographically disparate populations, and bring unique interests and expertise to their parent projects. 

 

The specific sites comprising RePORT India include the MV Diabetes Research Centre (MVDRC)  in Chennai, working with U.S. partners at the University of Massachusetts to study the impact of diabetes on TB severity among adults; Byramjee Jeejeebhoy Government Medical College (BJGMC) in Pune, and the National Institute for Research in Tuberculosis (NIRT) in Chennai working with U.S. partners at Johns Hopkins University to investigate host and microbial factors associated with active and latent TB infection in adults and children; PD Hinduja Hospital and Medical Research Center in Mumbai working with Johns Hopkins University on MDR-TB treatment outcomes, adverse effects, Mtb genotyping, and pharmacokinetic testing; Bhagawan Mahavir Medical Research Centre (BMMRC) in Hyderabad, working with the University of Texas Health Science Center to study the role of cellular immunity in preventing progression to active TB; Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER) in Puducherry, working with Boston University Medical Center to study risk factors for treatment relapse and progression to active TB; and Christian Medical College (CMC) in Vellore, working with the University of Washington to study the impact of adjunctive steroids for TB meningitis.

An Executive Committee has been constituted to provide leadership, governance, and guidance for the RePORT India Consortium. The consortium is also supported by a central bio-repository housed at the NIRT in Chennai, and a central data management center housed at the Centre for Health Research and Development-Society for Applied Studies-in Delhi.